The global Treatment-Resistant Depression Therapeutics Market is experiencing rapid growth as the prevalence of depression and anxiety disorders amongst adults continues to rise, compounded by an aging population. By 2033 it’s projected to reach US$4.0 Billion in accumulated value due entirely new treatments being developed through innovative routes such as nasal inhalants or direct intravenous administration – …